Smith & Nephew SNATS Debt/Equity Ratio 2010-2024 | SNN

Smith & Nephew SNATS debt/equity ratio for the quarter ending June 30, 2024 was 0.63.

  • Smith & Nephew SNATS average debt/equity ratio for 2023 was 0.47, a 0% increase from 2022.
  • Smith & Nephew SNATS average debt/equity ratio for 2022 was 0.47, a 11.32% decline from 2021.
  • Smith & Nephew SNATS average debt/equity ratio for 2021 was 0.53, a 7.02% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Smith & Nephew SNATS Debt/Equity Ratio 2010-2024 | SNN

  • Smith & Nephew SNATS average debt/equity ratio for 2023 was 0.47, a 0% increase from 2022.
  • Smith & Nephew SNATS average debt/equity ratio for 2022 was 0.47, a 11.32% decline from 2021.
  • Smith & Nephew SNATS average debt/equity ratio for 2021 was 0.53, a 7.02% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$205.5B
Stryker (SYK)$138.7B
Boston Scientific (BSX)$121.5B
Medtronic (MDT)$113.7B
EssilorLuxottica (ESLOY)$104.2B
Haleon (HLN)$48.6B
Lonza Group Ag (LZAGY)$45.9B
ResMed (RMD)$36.9B
Koninklijke Philips (PHG)$29.3B
Terumo (TRUMY)$27.8B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$20.3B
Insulet (PODD)$16.5B
Bio-Rad Laboratories (BIO)$9.3B
Demant (WILYY)$9.2B
BellRing Brands (BRBR)$7.7B
Lantheus Holdings (LNTH)$7.3B
ICU Medical (ICUI)$4.3B
Haemonetics (HAE)$3.9B
TG Therapeutics (TGTX)$3.9B
GN Store Nord (GNNDY)$3.8B
Perrigo (PRGO)$3.8B
Neogen (NEOG)$3.7B
Prestige Consumer Healthcare (PBH)$3.6B
Envista Holdings (NVST)$3.3B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.2B
LeMaitre Vascular (LMAT)$2B